Less than 2 months to #ASCO25! Join us to🗣️the current SoC➕how the data from #ASCO25 will change/reinforce our practice! InPerson: May 31st, 2025 Location📍Marriott Marquis Time: 6:30-9:00PM Register bit.ly/aioasco25 #AdvInOnc25 #bcsm #OncTwitter #gism #lcsm #gusm

Kicking off Mayo Clinic Comprehensive Cancer Center #gastrointestinalcancer meeting in beautiful Visit Santa Barbara

⁦Kim Reiss Binder (Kim Reiss)⁩ giving a masterful review on HRR and #pancreascancer ⁦Mayo Clinic⁩ #gicancer meeting in ⁦Visit Santa Barbara⁩

Excellent overview of ctDNA MRD by Dr. Yoshino highlighting the promising data with current limitations and the need for more RCTs Mayo Clinic Comprehensive Cancer Center Tanios Bekaii-Saab, MD #MRD #ctDNA #CRC Jeremy Jones

⁦Katrina Pedersen, MD, MS⁩ discussing the epidemic of young-onset #colorectalcancer ⁦Mayo Clinic Comprehensive Cancer Center⁩ #gicancers ⁦Visit Santa Barbara⁩

ctDNA-Guided Approaches Reveal Effective Adjuvant Agents in MRD+ CRC Tanios Bekaii-Saab, MD @mayoclinic #oncology #CRC hubs.li/Q03g60Vx0

Just released on JCO Oncology Practice our latest editorial on systemic therapies for advanced #HCC! IEO ascopubs.org/doi/10.1200/OP…

Phase III CodeBreaK 300: In chemorefractory KRAS G12C-mut mCRC, sotorasib 960mg + panitumumab improved PFS (5.7 vs 2.0 mo; HR 0.45) & ORR (30% vs 2%) vs SOC. OS trend favored combo (HR 0.70), but not statistically significant. #CRCsm #OncTwitter #GIonc ascopubs.org/doi/pdfdirect/…

That’s a wrap on #TexasLung25 — ending with the debate of the year! Osimertinib is set to be taken to jail… with a suspended sentence? Can’t wait to see the European sequel. Big thanks to Stephen V Liu, MD & #TinaCascone for putting together such a massive event. TLC Conference

Glad to have published these important findings for our patients with #HCC ✅19.6% alive at 5 years with STRIDE regimen #immunotherapy #longtermsurvival Humanitas University Humanitas Milano Journal of Hepatology Stephen L. Chan Ghassan Abou-Alfa

The FDA has approved nivolumab + ipilimumab for patients with unresectable or metastatic #HCC 👏 fda.gov/drugs/resource…

First time in Salt Lake City for the #ccfac25 - international consensus on research priorities. Honored to be part of this meeting as an early-career researcher, sharing insights on the promising role of radiomics and connecting with multidisciplinary professionals. Cholangiocarcinoma Foundation

ASCO25: 5-year update from CheckMate 577 — adjuvant nivolumab after CRT + surgery in esophageal/GEJ cancer. We knew the DFS win, but what about OS and long-term signals? Let’s break it down 🧵 #ASCO25 #GIonc #escc

#ASCO2025 A landmark study shows that structured exercise after adjuvant chemo for resected CRC improves both DFS and OS! I've long included this in survivorship counseling—great to see it validated. What does “exercise” mean here? ➡️ +10 MET-hours/week = ~150 min/week of brisk

Please watch our video on what treatment strategies are available for patients with advanced #HCC who are ineligible for #immunotherapy or with progression on #IO Amit G Singal HCC CONNECT Humanitas University Humanitas Milano

ESMO GI 2025 | #MATTERHORN Update. Perioperative Durvalumab + FLOT 🆚 Placebo + FLOT in resectable G/GEJ adenocarcinoma 🎯 Primary endpoint met 🔹 EFS HR 0.71 (95% CI: 0.58–0.86, p<0.001) 🔹 mEFS: NR vs 32.8 mo 🔹 OS HR: 0.78 (p=0.025, NS at interim) 🔹 QoL ✅ (no

Keynote lecture on Epidemiology: Trends and causes of GI cancers at #ESMOGI25 by Dr Elisabete Weiderpass (views are my own) Elisabete Weiderpass. GI cancers attributable to #alcohol drinking #ESMOAmbassadors #GIOnc ESMO - Eur. Oncology

Grateful to ESMO - Eur. Oncology for the chance to share my perspective on agnostic cancer therapies and their role in advancing precision medicine in GI tumours. Huge thanks to the incredible chairs and speakers of this session - I feel very privileged to have been a part of it. #ESMOGI25

🧵Dutch population-based cohort at #ESMOGI25 on definitive CRT for esophageal adenocarcinoma (n=872) 🎯mPFS 11.2 mo (95% CI: 8.8–13.4) 🎯mOS: 18.9 mo | 1y: 66.5% | 3y: 24.9% | 5y: 13.5% ▪️OS worse with higher stage (HR stage I/II vs III: 1.53; vs IVa: 1.60; p<0.001) A dCRT

⁦Daniel Ahn⁩ from ⁦Mayo Clinic Comprehensive Cancer Center⁩ presenting positive results for his study with #parp inhibitor Olaparib in #HRR #cholangiocarcinoma ⁦ESMO - Eur. Oncology⁩ #esmogi25 ⁦Cholangiocarcinoma Foundation⁩ ⁦Milind Javle⁩ ⁦Mitesh Borad, M.D.⁩